GlassScriptPhysician profile
Kathryn N Hester
NPI 1336350040
$4,523.75
in general payments reported to CMS, 2019-2025
24 companies · $607 in 2025
The $607 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $516 · 2021: $620 · 2022: $362 · 2023: $559 · 2024: $656 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785 · Education: $37.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.04 |
| Education | $37.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,354.04 | 2019-2025 | |
| Amgen INC. | $831.81 | 2019-2025 | Enbrel, Otezla, Tavneos |
| E.R. Squibb & Sons, L.L.C. | $742.91 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $247.12 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $202.89 | 2019-2023 | Benlysta |
| Lilly USA, LLC | $150.34 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $136.05 | 2019-2023 | Stelara, Remicade, Simponi |
| Novartis Pharmaceuticals Corporation | $112.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.71 | 2023-2025 | Ofev, Cyltezo |
| Pfizer INC. | $110.67 | 2020-2021 | |
| Ucb, INC. | $107.29 | 2019-2025 | Bimzelx |
| Genentech USA, INC. | $96.12 | 2019-2020 | |
| Organon LLC | $51.17 | 2024-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $47.75 | 2023-2024 | Tyenne, Idacio |
| Boston Scientific Corporation | $38.87 | 2023-2025 | Wavewriter Alpha Prime 16, Varithena Administration Pack |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $37.27 | 2023 | Yuflyma |
| Horizon Therapeutics Plc | $24.77 | 2019-2022 | |
| Abiomed | $20.53 | 2024 | Impella |
| Sandoz INC. | $18.72 | 2023 | Hyrimoz |
| Antares Pharma, INC. | $17.77 | 2019 | |
| Sobi, INC | $17.29 | 2025 | |
| Aurinia Pharma U.S., INC. | $15.42 | 2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $15.17 | 2021 | |
| Genzyme Corporation | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.